Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bulevirtide + brelovitug
- Development stage
- Unknown
- Lead developer
- Mirum Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
bulevirtide + brelovitug is a combination therapy under investigation for the treatment of chronic hepatitis delta virus (HDV) infection. It consists of bulevirtide, a first-in-class entry inhibitor, and brelovitug (BJT-778), a fully human IgG1 monoclonal antibody. Bulevirtide is a synthetic lipopeptide that mimics the pre-S1 domain of the hepatitis B virus (HBV) large surface protein, binding to and blocking the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, which is essential for HBV and HDV entry. Brelovitug targets the hepatitis B surface antigen (HBsAg), neutralizing circulating virions and promoting the clearance of HBsAg-containing particles. The combination is being developed by Mirum Pharmaceuticals (following its acquisition of Bluejay Therapeutics) and is currently being evaluated in the Phase 3 AZURE-2 clinical trial to determine if the dual mechanism of entry inhibition and antigen clearance provides superior efficacy over bulevirtide monotherapy.
- Other names
- BJT-778 + bulevirtide
02
Targets
NTCP (Na+-taurocholate cotransporting polypeptide)
Beyond the preview
Go deeper on bulevirtide + brelovitug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bulevirtide + brelovitug.